DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Summary for Patent: 9,566,272
|Title:||Compositions and methods for treating diseases of the nail|
|Abstract:||Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed.|
|Inventor(s):||Winckle; Gareth (Biot, FR), Fieldson; Gregory T. (Morgantown, WV)|
|Assignee:||DOW PHARMACEUTICAL SCIENCES, INC. (Petaluma, CA)|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for patent 9,566,272|
1. A method for the treatment of onychomycosis comprising topically applying to the surface of the nail of an individual suffering from onychomycosis a pharmaceutical
composition comprising ethanol, diisopropyl adipate, C12-15 alkyl lactate, cyclomethicone, and (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidine-1-yl)-1-(1H-1,2,4- -triazole-1-yl)butane-2-ol; wherein the composition is formulated as a solution;
wherein the ethanol is present in the composition at a concentration of at least 50% w/w; wherein the cyclomethicone is present in the composition at a concentration less than 25% w/w; wherein the diisopropyl adipate and C12-15 alkyl lactate are
present in the composition at a total concentration between 15 and 50% w/w; wherein the concentration of (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidine-1-yl)-1-(1H-1,2,4- -triazole-1-yl)butane-2-ol in the composition is about 10% w/w; and
wherein the application of the composition is in an amount and for a time sufficient to ameliorate the symptoms of the onychomycosis.
2. The method of claim 1, wherein the concentration of the cyclomethicone in the pharmaceutical composition is between 10% and 15% w/w.
3. The method of claim 1, wherein the pharmaceutical composition does not comprise a polymeric film forming compound.
4. The method of claim 1, wherein: the concentration of the ethanol in the pharmaceutical composition is at least 50% w/w; the concentration of the cyclomethicone in the pharmaceutical composition is between 10% and 15% w/w; the combined concentration of the diisopropyl adipate and the C12-15 alkyl lactate in the pharmaceutical composition is between 15% and 50% w/w; and wherein the pharmaceutical composition does not comprise a polymeric film forming compound.
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.